is a synthetic antiviral agent used in prophylaxis and in treating the early stages of uncomplicated influenza A illness. We describe a stable isotope-dilution assay involving capillary gas chromatography/mass spectrometry. We used 200 ng of d3-rimantadine, added to 1 mL of plasma, as the internal standard.
Tubes from 86 elderly adults participating in a placebo-controlled, double-blind study of rimantadine treatment of influenza A virus infections. Samples were collected 1 h after the morning dose on days 2 and 7. The blood was centrifuged; the plasma was removed and stored in screwtop vials at -20 #{176}C until analyzed.
All patients were nursing-home residents (82% female, median age 86 years) who had experienced the onset of influenza-like illness within the previous 48 h. Patients were randomly assigned to receive treatment with rimantadine, 200 mg upon enrollment and 100 mg twice daily, or placebo, for seven days. If subjects were enrolled in this study after 16:00 hon the first day, they received 
DIscussIon
The base peaks in the mass spectra of rimantadine and
